Biostock: CombiGene is preparing for the clinic

CombiGene’s year-end report for 2020, which was published last week, summarised what can be seen as a financially successful year with three new share issues and three series of warrants that brought in a total of SEK 89 million before issue costs. During the year, three research advances were also presented in preparation of the first study in humans with the gene therapy CG01 in epilepsy, which is planned to be initiated next year. CombiGene’s lipodystrophy project has also advanced and the company recently announced that they have received development funding from the EU Eurostars programme.

Read the full article about CombiGene at

This is a pressrelease from BioStock – Connecting Innovation & Capital.